Top of the morning, and a fine one it is. Our shortest person successfully departed for the local schoolhouse for another day of learning, our official mascot is snoozing happily in his designated snoozing corner, and the coffee kettle is firing up yet another cup of stimulation (maple pecan is the favorite today). All of which is to say we can focus on the usual matters at hand — foraging for items of interest. Speaking of which, here are a few tidbits to help you along on your own journey. Hope all goes well today and, as always, please do keep in touch.

Local governments in regions hard hit by the U.S. opioid crisis have opted out of massive litigation taking aim at the drug industry over the crisis, potentially weakening a novel legal mechanism created to help settle thousands of lawsuits, Reuters writes. Overall, 98% of some 34,000 local governments agreed to be bound by a class action against drug makers and distributors. But 541 local governments that opted out are raising the prospect that companies could face expensive trials even if they settled with the class.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy